The reiteration of a Buy rating and the maintenance of a $27 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on Inhibikase Therapeutics' stock price. The analyst's bullish stance suggests a strong belief in the company's future performance and growth prospects, which could influence investor sentiment positively.